F13B

Across TCGA pan-cancer cohorts, F13B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated F13B data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher F13B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated F13B expression acts as an unfavorable survival marker.

SCLC, LIHC, and SKCM are the cancer types where F13B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	III,IV	0.055	0.640	<.001	12	view →
LIHC	OS	Median	All	0.152	0.688	.017	9	view →
SKCM	OS	Median	IV	0.133	0.621	.019	9	view →
BRCA	DFS	Median	III,IV	0.141	0.796	<.001	6	view →
PRAD	DFS	Median	All	0.617	0.886	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

F13B–SCLC (OS)

Open the SCLC breakdown →